Envafolimab (KN035), TRACON has rights to develop and commercialize envafolimab in sarcoma in North America.
![logo_3dmed](https://traconpharma.com/wp-content/uploads/2023/04/logo_3dmed.png)
![logo_alphamab](https://traconpharma.com/wp-content/uploads/2023/04/logo_alphamab.png)
1
INDICATION
Undifferentiated Pleomorphic Sarcoma (UPS)/Myxofibrosarcoma (MFS) in the U.S.
Solid Tumors (in U.S.)
Solid Tumors (in Japan)
Solid Tumors (in China)
Gastric Cancer (in China)
MSI-H Advanced Solid Tumors (in China)
Biliary Tract Cancer (in China)
YH001
![logo_eucure](https://traconpharma.com/wp-content/uploads/2023/04/logo_eucure.png)
2
Solid Tumors
TRC102
INDICATION
Advance Localized Lung Cancer
Lung, Solid Tumors
1 Strategic partnership with 3D Medicines and Alphamab Oncology
2 Strategic partnership with Eucure Biopharma
3 Strategic partnership with I-Mab Biopharma